JeffreySWeberMD

Oncology • New York, NY

Physician

Join to view full profile

Dr. Weber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weber's full profile

Already have an account?

Office
160 East 34th Street
7th Floor
New York, NY 10016

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
University of California (San Diego) Medical CenterInternship, Internal Medicine, 1980 - 1981
New York University School of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1994 - Present
NY State Medical License 1983 - 2025
FL State Medical License 2007 - 2017
MD State Medical License 1985 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase I/II Study of Dasatinib and Dacarbazine Start of enrollment: 2007 Nov 01
Completed
Phase 1, Phase 2
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Start of enrollment: 2009 Jan 23
Completed
Phase 2
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 Start of enrollment: 2009 Oct 01
Completed
Phase 1
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Start of enrollment: 2010 Aug 13
Completed
Phase 1
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC Start of enrollment: 2011 Oct 11
Terminated
Phase 2
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma Start of enrollment: 2012 Feb 17
Completed
Phase 1
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Start of enrollment: 2012 Jul 27
Completed
Phase 1
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Start of enrollment: 2012 Aug 03
Active, not recruiting
Phase 2
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Start of enrollment: 2012 Oct 09
Active, not recruiting
Not Applicable
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma Start of enrollment: 2014 Jan 07
Completed
Phase 1
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Start of enrollment: 2014 Sep 29
Terminated
Phase 1, Phase 2
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2019 Jun 11
Active, not recruiting
Phase 2
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma Start of enrollment: 2019 Oct 28
Active, not recruiting
Phase 3
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2022 Dec 16
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

59 citations
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber
European Journal of Cancer. 2021-02-01
788 citations
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas, Omid Hamid, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok
JAMA. 2016-04-19
64 citations
Improved Survival of Patients With Melanoma Brain Metastases in the Era of Targeted BRAF and Immune Checkpoint Therapies
Sarah Sloot, Yian A. Chen, Xiuhua Zhao, Jamie L. Weber, Jacob J. Benedict
Cancer. 2018-01-15

Journal Articles

The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19-Related Systemic Inflammatory Response
Steven J O'Day, Walter J Urba, Jeffrey S Weber, Journal For Immunotherapy of Cancer

Lectures

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
2019 ASCO Annual Meeting - 6/1/2019
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Remembering a Pioneer in Melanoma and Immunotherapy: Jeffrey S. Weber, MD, PhD, FASCOAugust 27th, 2024
Oncologists Celebrate the Legacy of Dr. Jeffrey S. Weber, “the Consummate Physician-Scientist”August 26th, 2024
Outcomes in Resected Melanoma Influenced by Timing of RecurrenceAugust 8th, 2024
Join now to see all